A robust clinical
development plan
CONV01-α
CONV01-α (Ac-225 rosopatamab tetraxetan) is a proprietary, best-in-class actinium-225 labeled radioantibody with proven efficacy and safety in multiple Phase 1/2 trials in patients with prostate cancer.
Recruitment for CONVERGE-01 is underway and planning for future trials continues.
Compassionate use statement
Convergent Therapeutics, Inc. (“Convergent”) is a biotechnology company focused on developing next-generation targeted radiotherapies to treat cancer. At this time, Convergent does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational product whenever possible. Clinical trials are designed, conducted, and monitored to ensure that the safety and effectiveness of investigational products are appropriately evaluated before the results from the trials are submitted to regulatory agencies for review with the intent to make them more broadly available to patients. You and your health care provider may learn more about our clinical trial visiting www.clinicaltrials.gov and searching for Convergent Therapeutics. If you are a health care provider who is interested in learning more about one of our investigational products, or a physician with questions about participation in one of our clinical trials, please submit a request to info@convergentrx.com.
| Indication | Target | Regimen |
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
|
Notes |
| Prostate Cancer | PSMA | Monotherapy | Includes pre- and post- Lu-177-PSMA-radioligand patient cohorts |
|
| PSMA | + PD-1 inhibitor | Multisite study led by
|
||
| PSMA | + ß-Radiopharmaceutical | Single-site study led by
|
||
| Non-Prostate Cancer | PSMA | Monotherapy |
| Indication | Prostate Cancer |
| Target | PSMA |
| Regimen | Monotherapy |
|
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
|
|
| Notes | Includes pre- and post- Lu-177-PSMA-radioligand patient cohorts |
| Indication | |
| Target | PSMA |
| Regimen | + PD-1 inhibitor |
|
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
|
|
| Notes | Multisite study led by
|
| Indication | |
| Target | PSMA |
| Regimen | + ß-Radiopharmaceutical |
|
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
|
|
| Notes | Single-site study led by
|
| Indication | Non-Prostate Cancer |
| Target | PSMA |
| Regimen | Monotherapy |
|
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
|
|
| Notes |
Novel
α-radioantibodies
We are leveraging best-in-class biology to create Ac-225 radioantibodies against validated cancer targets.
| Indication | Target | Regimen |
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
|
Notes |
| Solid Tumors | Undisclosed | Undisclosed |
| Indication | Solid Tumors |
| Target | Undisclosed |
| Regimen | Undisclosed |
|
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
|
|
| Notes |
Potential future
applications
Radioantibodies are a versatile technology and may be combined with other treatment options.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean fermentum pellentesque nunc, vel convallis urna auctor eget. Vestibulum feugiat libero diam, ut interdum eros ornare quis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean fermentum pellentesque nunc, vel convallis urna auctor eget. Vestibulum feugiat libero diam, ut interdum eros ornare quis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean fermentum pellentesque nunc, vel convallis urna auctor eget. Vestibulum feugiat libero diam, ut interdum eros ornare quis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean fermentum pellentesque nunc, vel convallis urna auctor eget. Vestibulum feugiat libero diam, ut interdum eros ornare quis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean fermentum pellentesque nunc, vel convallis urna auctor eget. Vestibulum feugiat libero diam, ut interdum eros ornare quis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean fermentum pellentesque nunc, vel convallis urna auctor eget. Vestibulum feugiat libero diam, ut interdum eros ornare quis.